SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells
Nicole C Dubois, April M Craft, Parveen Sharma, David A Elliott, Edouard G Stanley, Andrew G Elefanty, Anthony Gramolini, Gordon Keller
Nature Biotechnology | NATURE PUBLISHING GROUP | Published : 2011
Awarded by Canadian Institute of Health Research (CIHR)
Awarded by Ontario's Ministry of Research and Innovation (MRI)
Awarded by Heart and Stroke Foundation of Ontario
We would like to thank members of the Keller laboratory for discussion and critical reading of the manuscript, G. Daley (Harvard Medical School, Boston) for providing the MSC-iPS1 and 38-2 cell line, B. Neel for providing the Sirpa-mutant mice and for discussion and suggestions, L. Ailles, J. Paterson and E. Hyatt from the antibody core facility, R. Hamilton for assistance in obtaining fetal tissue samples and the Sick Kids/UHN Flow Cytometry Facility for their assistance with cell sorting. This work was supported by funding from VistaGen Therapeutics (San Francisco) and by grants from Canadian Institute of Health Research (CIHR, MOP-84524) and Ontario's Ministry of Research and Innovation (MRI, GL2-CBD3P3) to G.K. N.C.D. was supported by a Swiss National Foundation postdoctoral fellowship. A.G. and P.S. were supported by the Heart and Stroke Foundation of Ontario (T6281 and NS6636) and CIHR (MOP-106538). A.G.E., E.G.S. and D.A.E. are supported by grants from the Australian Stem Cell Centre, the National Health and Medical Research Council (NHMRC, Australia) and the National Heart Foundation (Australia). E.G.S. and A.G.E. are Senior Research Fellows of the NHMRC (Australia).